Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Headquartered in Boston, Massachusetts, the company engineers "off-the-shelf" cell therapies with chimeric antigen receptors (CARs) to facilitate durable immune responses. Its distinctive approach leverages gamma delta T cells to target specific disease indications without requiring patient-specific cell harvesting.